Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $30.35, but opened at $31.82. Collegium Pharmaceutical shares last traded at $31.35, with a volume of 26,389 shares traded.
Analysts Set New Price Targets
COLL has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Piper Sandler reaffirmed a "neutral" rating and issued a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Wall Street Zen downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, July 5th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and a consensus price target of $43.75.
Get Our Latest Report on Collegium Pharmaceutical
Collegium Pharmaceutical Price Performance
The stock has a market cap of $1.06 billion, a PE ratio of 27.05 and a beta of 0.64. The company has a debt-to-equity ratio of 3.30, a current ratio of 1.08 and a quick ratio of 1.01. The business has a fifty day moving average of $29.48 and a 200 day moving average of $29.55.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The firm had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same period in the prior year, the business earned $1.45 EPS. The company's quarterly revenue was up 22.7% on a year-over-year basis. Sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.
Collegium Pharmaceutical declared that its board has approved a share repurchase program on Monday, July 7th that permits the company to buyback $150.00 million in outstanding shares. This buyback authorization permits the specialty pharmaceutical company to buy up to 15.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its stock is undervalued.
Insider Buying and Selling
In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $30.62, for a total transaction of $202,122.62. Following the transaction, the director owned 70,658 shares of the company's stock, valued at $2,163,547.96. This trade represents a 8.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 2.51% of the stock is currently owned by corporate insiders.
Institutional Trading of Collegium Pharmaceutical
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Exchange Traded Concepts LLC raised its position in shares of Collegium Pharmaceutical by 4.3% during the 2nd quarter. Exchange Traded Concepts LLC now owns 65,132 shares of the specialty pharmaceutical company's stock worth $1,926,000 after purchasing an additional 2,706 shares during the period. Rhumbline Advisers raised its position in shares of Collegium Pharmaceutical by 3.1% during the 1st quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company's stock worth $3,332,000 after purchasing an additional 3,400 shares during the period. Belpointe Asset Management LLC acquired a new stake in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $408,000. Fortis Capital Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $408,000. Finally, Intech Investment Management LLC raised its position in shares of Collegium Pharmaceutical by 10.1% during the 1st quarter. Intech Investment Management LLC now owns 73,908 shares of the specialty pharmaceutical company's stock worth $2,206,000 after purchasing an additional 6,776 shares during the period.
Collegium Pharmaceutical Company Profile
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Recommended Stories
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.